Oncternal Provides Business Update and Announces First Quarter 2021 Financial ResultsemailcareyMay 6, 20211 min readUpdated: May 12, 2021Interim results of a Phase 1b trial of cirmtuz umab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast cancer compare favorably to historical single-agent paclitaxel data (57% ORR vs. ~30% ORR historical single-agent paclitaxel)In a preclinical study of cirmtuzumab added to high-grade serous ovarian cancer cell lines, cirmtuzumab demonstrated single agent activity and enhanced the anti-proliferative effect of commonly used chemotherapiesOncternal appointed Chase Leavitt as General CounselOncternal presenting clinical updates on cirmtuzumab in MCL/CLL and TK216 in Ewing sarcoma at the ASCO Annual Meeting in June 2021Management to host webcast today at 5:00 pm EThttps://investor.oncternal.com/news-releases/news-release-details/oncternal-provides-business-update-and-announces-first-quarter-0
Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates- First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA® (lefamulin) and SIVEXTRO®...
Equillium Announces Three Abstracts Accepted for Presentation at the 104th AAI Annual MeetingPresentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab,...
MatriSys Bioscience Names Joyce Rico as Chief Medical OfficerMatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced the hiring of Joyce...
Комментарии